GNC T02
Alternative Names: GNC-T02Latest Information Update: 24 Dec 2021
At a glance
- Originator SystImmune
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 24 Dec 2021 Discontinued - Preclinical for Solid tumours in USA (Parenteral) (SystImmune pipeline, December 2021)
- 01 May 2019 SystImmune plans a phase I trial for Solid tumours (Parenteral) by 2021 (SystImmune pipeline, May 2019)
- 01 May 2019 Preclinical trials in Solid tumours in USA (Parenteral) before May 2019 (SystImmune pipeline, May 2019)